Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Al18F-NOTA-LM3 PET/CT in Tumor-Induced Osteomalacia
NCT07366099Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of Al18F-NOTA-LM3 in tumor-induced osteomalacia (TIO), sponsored by Peking Union Medical College Hospital. Primary endpoint: Diagnostic value at 6 months. Started Mar 2023; status: recruiting.
02
Drugs
Al18F-NOTA-LM3
03
Conditions
tumor-induced osteomalacia (TIO)
Beyond the preview
Go deeper on NCT07366099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366099.